The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics will have a significant impact on this trend. Some generic LABA/ICS FDCs and LAMAs have already launched in the United States and Europe, and more will reach the market in the coming years. Although physicians will welcome additional treatment options for this chronic disease as a result of the development of novel drug classes, including biologics (e.g., IL-33, IL-13/IL-4, IL-5 inhibitors) and novel inhaled and nebulized therapies (e.g., PDE3/4 inhibitors), significant unmet need remains for therapies that can repair lung tissue or halt disease progression.
QUESTIONS ANSWERED
Will LABA/LAMA FDCs continue to gain market share, or will generic therapies or branded LABA/LAMA/ICS FDCs threaten these agents?
What are key opinion leaders’ insights on current treatment options (e.g., GSK’s Advair, Trelegy, Breo; GSK / Innoviva’s Anoro; BI’s Spiriva, Stiolto / Spiolto; AstraZeneca’s Breztri, Symbicort)? What factors drive physicians’ treatment decisions?
How will the market evolve over the next 10-year forecast period?
Which emerging therapies have the most potential for uptake? Will nebulized therapies be accepted? Will the use of IL-5 inhibitors be accepted for COPD? How will the launch of these and other biologics influence the COPD market?
What is the unmet need for COPD?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
What factors are driving the market for chronic obstructive pulmonary disease?
What factors are constraining the market for chronic obstructive pulmonary disease?
Patient share of select drug classes for mild to moderate COPD in the G7: 2021-2031
Patient share of select drug classes for severe to very severe COPD in the G7: 2021-2031
Drug-class specific trends
Brand and generic patient share of tiotropium in COPD: 2021-2031
Major-market sales of LAMAs in COPD: 2021-2031
Brand and generic sales of LABA/ICSs in COPD: 2021-2031
U.S. patient share of LABA/ICS combinations in COPD: 2021-2031
EU5 patient share of LABA/ICS combinations in COPD: 2021-2031
Japan patient share of LABA/ICS combinations in COPD: 2021-2031
Major-market sales and patient share of LABA/LAMA combinations for COPD: 2021-2031
Major-market patient share of LABA/LAMA/ICS FDCs for mild to moderate COPD: 2021-2031
Major-market patient share of LABA/LAMA/ICS FDCs for severe to very severe COPD: 2021-2031
Forecast
Market forecast assumptions - COPD 2021-2031 - October 2022
Brand and generic patient share of tiotropium in COPD: 2021-2031
Major-market sales of LAMAs in COPD: 2021-2031
Brand and generic sales of LABA/ICSs in COPD: 2021-2031
U.S. patient share of LABA/ICS combinations in COPD: 2021-2031
EU5 patient share of LABA/ICS combinations in COPD: 2021-2031
Japan patient share of LABA/ICS combinations in COPD: 2021-2031
Major-market sales and patient share of LABA/LAMA combinations for COPD: 2021-2031
Major-market patient share of LABA/LAMA/ICS FDCs for mild to moderate COPD: 2021-2031
Major-market patient share of LABA/LAMA/ICS FDCs for severe to very severe COPD: 2021-2031
Market forecast dashboard - COPD 2021-2031 - October 2022
Brand and generic patient share of tiotropium in COPD: 2021-2031
Major-market sales of LAMAs in COPD: 2021-2031
Brand and generic sales of LABA/ICSs in COPD: 2021-2031
U.S. patient share of LABA/ICS combinations in COPD: 2021-2031
EU5 patient share of LABA/ICS combinations in COPD: 2021-2031
Japan patient share of LABA/ICS combinations in COPD: 2021-2031
Major-market sales and patient share of LABA/LAMA combinations for COPD: 2021-2031
Major-market patient share of LABA/LAMA/ICS FDCs for mild to moderate COPD: 2021-2031
Major-market patient share of LABA/LAMA/ICS FDCs for severe to very severe COPD: 2021-2031
Etiology and pathophysiology
Disease overview
Etiology
Causative factors for COPD
Pathophysiology
Mechanisms contributing to symptoms and progression of COPD
Lung anatomy and pathogenic processes in COPD
Inflammatory mechanisms of COPD
Disease progression
Key pathways and drug targets
Potential biomarkers of COPD
Epidemiology
Key findings
Epidemiology populations
Disease definition
Methods
Sources used for total prevalent cases of COPD
Total prevalent cases of COPD : 2021-2031 (thousands)
Disease definition
Methods
Sources used for diagnosed prevalent cases of COPD
Diagnosed prevalent cases of COPD: 2021-2031 (thousands)
Disease definition
Methods
Sources used for COPD segmented by severity
Diagnosed prevalent cases of mild to moderate COPD: 2021-2031 (thousands)ttttttt
Diagnosed prevalent cases of severe to very severe COPD: 2021-2031 (thousands)tttttttttt
Number of drug-treated prevalent cases of mild to moderate COPD in the major pharmaceutical markets: 2020-2030 (thousands)
Number of drug-treated prevalent cases of severe to very severe COPD in the major pharmaceutical markets: 2021-2031 (thousands)
Disease definition
Methods
Sources used for acute exacerbations of COPD
Acute exacerbations of COPD: 2021-2031
Disease definition
Methods
Sources used for eosinophilic COPD
Diagnosed prevalent cases of eosinophilic COPD: 2021-2031 (thousands)
Current treatment
Key findings
Treatment goals
Key endpoints used in clinical trials for COPD
Key current therapies
Overview
Mechanism of action of key current drug classes used for COPD
Current treatments used for COPD
Market events impacting the use of key current therapies in COPD
Advantages and disadvantages of tiotropium
Advantages and disadvantages of aclidinium
Advantages and disadvantages of glycopyrronium
Advantages and disadvantages of nebulized glycopyrronium
Advantages and disadvantages of revefenacin
Advantages and disadvantages of umeclidinium
Expert insight: LAMAs
Advantages and disadvantages of indacaterol
Advantages and disadvantages of olodaterol
Expert insight: LABAs
Advantages and disadvantages of indacaterol / glycopyrronium
Advantages and disadvantages of vilanterol / umeclidinium
Advantages and disadvantages of formoterol / aclidinium
Advantages and disadvantages of olodaterol / tiotropium
Advantages and disadvantages of formoterol / glycopyrronium
Expert insight: LABA/LAMA FDCs
Advantages and disadvantages of salmeterol / fluticasone propionate
Advantages and disadvantages of formoterol / budesonide
Advantages and disadvantages of vilanterol / fluticasone furoate
Expert insight: LABA/ICS FDCs
Advantages and disadvantages of formoterol / glycopyrronium / beclomethasone
Advantages and disadvantages of vilanterol / umeclidinium / fluticasone furoate
Advantages and disadvantages of formoterol / glycopyrronium / budesonide
Expert insight: LABA/LAMA/ICS FDCs
Advantages and disadvantages of roflumilast
Expert insight: roflumilast
Advantages and disadvantages of short-acting bronchodilators
Expert insight: short-acting bronchodilators
Advantages and disadvantages of methylxanthines
Expert insight: methylxanthines
Medical practice
Overview
Factors influencing drug selection in COPD
Inhaler devices for COPD
Treatment decision tree for COPD: United States
Treatment decision tree for COPD: Europe
Treatment decision tree for COPD: Japan
Unmet need overview
Current and future attainment of unmet needs in chronic obstructive pulmonary disease
Top unmet needs in chronic obstructive pulmonary disease: current attainment and future attainment
Expert insight: unmet needs in chronic obstructive pulmonary disease
Drug pipeline
Pipeline
Regulatory Milestones
Indication Comparison
Emerging therapies
Key findings
Key emerging therapies
Key therapies in development for COPD
Estimated launch dates of key emerging therapies for the treatment of COPD
Dupilumab profile
Analysis of the clinical development program for dupilumab
Expert insight: dupilumab
Expectations for launch and sales opportunity of dupilumab in COPD
Benralizumab profile
Analysis of the clinical development program for benralizumab
Expert insight: benralizumab
Expectations for launch and sales opportunity of benralizumab in COPD
Mepolizumab profile
Analysis of the clinical development program for mepolizumab
Expert insight: mepolizumab
Expectations for launch and sales opportunity of mepolizumab in COPD
Ensifentrine profile
Analysis of the clinical development program for ensifentrine
Expert insight: ensifentrine
Expectations for launch and sales opportunity of ensifentrine in COPD
Itepekimab profile
Analysis of the clinical development program for itepekimab
Expectations for launch and sales opportunity of itepekimab in COPD
Tozorakimab profile
Analysis of the clinical development program for tozorakimab
Expectations for launch and sales opportunity of tozorakimab in COPD
Expert insight: IL-33 inhibitors
Early-phase pipeline analysis
Select compounds in early-phase development for COPD
Access & reimbursement overview
Region-specific reimbursement practices
Key market access considerations in COPD: United States
General reimbursement environment: United States
Key market access considerations in COPD: EU5
General reimbursement environment: EU5
Key market access considerations in COPD: Japan
General reimbursement environment: Japan
Appendix
Abbreviations
COPD bibliography
Anupama Ashish Joshi
Anupama Joshi, M.S. (Pharm.),Healthcare Research & Data Analyst, Immune and Inflammation. Anupama is an analyst on the Immune and Inflammation team at Clarivate. Her focus is on respiratory diseases, particularly chronic obstructive pulmonary disease. Prior to joining Clarivate, Ms. Joshi was a research scientist in Dr. Reddy’s Laboratories. She obtained her master’s degree in pharmaceutical analysis from the National Institute of Pharmaceutical Education and Research (NIPER), S.A.S. Nagar (Mohali), India.
Navya Vardhan
Navya Vardhan, M.Sc., Epidemiologist, Epidemiology. She obtained her M.Sc. in biostatistics and demography from the International Institute for Population Sciences in Mumbai. She also holds a B.Sc. in mathematics.